Statins reduce adverse cardiovascular events in both primary and secondary prevention settings. Despite their use, however, a residual burden of cardiovascular events continues to remain; in part this residual risk is related to low high-density lipoprotein (HDL) cholesterol levels. Therefore, HDL-based interventions that either raise HDL cholesterol levels or improve HDL function have become the next target for atherosclerosis management.